Author: Nicholas Maithya

Editas Medicine Inc (NASDAQ:EDIT) Reports USPTO Decision Positive To Broad Institute In CRISPR Intervention
Health Technology

Editas Medicine Inc (NASDAQ:EDIT) Reports USPTO Decision Positive To Broad Institute In CRISPR Intervention

Editas Medicine Inc (NASDAQ:EDIT) reported that the USPTO released a favorable verdict in the CRISPR intervention between the University of Vienna, the University of California, the Broad Institute, Inc. and Emmanuelle Charpentier pertaining specific CRISPR-Cas9 patents the firm solely licenses from Broad. The USPTO approved Broad’s objective for “No Interference […]

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Progresses With Patients Enrollment Process In Pancreatic Cancer Clinical Trial
Decliners Health

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Progresses With Patients Enrollment Process In Pancreatic Cancer Clinical Trial

Pharmacyte Biotech Inc (OTCMKTS:PMCB) is successfully making progress with its enrollments process in a pivotal clinic trial targeting advanced, inoperable pancreatic cancer. It started with the enrollment after the FDA approved its pre-IND request meeting. A host of oncologists, clinicians and renowned scientists will discuss with the U.S. regulatory agency […]

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Gears Up For Phase-2 Clinical Trials Of Ralinepag
Health

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Gears Up For Phase-2 Clinical Trials Of Ralinepag

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued a press release stating that the enrollment of the ralinepag phase-2 clinical trials, is now closed, with 60 patients enrolled worldwide. It should be noted here that the drug has been developed as a treatment for pulmonary arterial hypertension. The announcement also revealed that the […]